PLASMA PROLACTIN LEVELS AFTER ACUTE AND SUBCHRONIC ORAL ADMINISTRATION OF DOMPERIDONE AND OF METOCLOPRAMIDE: A CROSS‐OVER STUDY IN HEALTHY VOLUNTEERS

@article{Brouwers1980PLASMAPL,
  title={PLASMA PROLACTIN LEVELS AFTER ACUTE AND SUBCHRONIC ORAL ADMINISTRATION OF DOMPERIDONE AND OF METOCLOPRAMIDE: A CROSS‐OVER STUDY IN HEALTHY VOLUNTEERS},
  author={J R Brouwers and Johanna Assies and Wilmar M. Wiersinga and G. H. Huizing and G. N. J. Tytgat},
  journal={Clinical Endocrinology},
  year={1980},
  volume={12}
}
Domperidone is a new potent anti‐emetic drug which, in contrast with metoclo‐pramide, does not cross the blood brain barrier. The aim of the present study was to find out whether peripheral dopaminergic blockage by domperidone causes prolactin release, and if so, whether this prolactin release persists during longer‐term treatment. For comparison, metoclopramide, which blocks both peripheral and central dopamine receptors, was studied using a cross‐over trial design. After acute oral… Expand
Domperidone; secretion in breast milk and effect on puerperal prolactin levels
Summary. The possible effect on the infant of dopamine antagonists used to promote lactation is cause for concern. Domperidone (Motilium) may be safer than other drugs in this group as it does notExpand
Effects of sustained hyperprolactinemia induced by chronic treatment with domperidone on central dopaminergic systems in the rat.
TLDR
It can be surmised that sustained hyperprolactinemia may induce tolerance in hypothalamic Tuberoinfundibular neurons involved in the inhibitory control of PRL secretion and a change in the kinetic properties of pituitary DA receptors, but it does not consistently affect the activity of the nigro-striatal DA system. Expand
Itraconazole and domperidone: a placebo-controlled drug interaction study
TLDR
Itraconazole significantly increased plasma domperidone concentrations and prolactin levels and reduced the slope of the linear relationship, probably due to a reduced first pass elimination by inhibition of CYP3A and/or MDR1. Expand
Effects of domperidone on serum prolactin levels in rats with hypothalamic deafferentation.
TLDR
Results indicated that domperidone, at least at high concentrations, acts through the caudal part of the hypothalamus to stimulate prolactin secretion. Expand
Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness
TLDR
The prolactin response to 20 mg of domperidone, a peripheral dopamine (DA) blocking agent, was evaluated in a group of 16 drug-free, acute, young schizophreniform and schizophrenic males and in agroup of age-matched normal males, where the PRL responses were blunted in both patient groups. Expand
Effect of domperidone-induced hyperprolactinaemia on the menstrual cycle; a placebo-controlled study
TLDR
Domperidone, a dopamine receptor antagonist which does not cross the blood-brain barrier and has few side effects, causes a greater than 10-fold increase in serum prolactin levels in female subjects is studied for fertility control. Expand
Differences in cardiac but not in neuroendocrine responses in healthy volunteers after administration of two antimuscarinic agents, atropine and pirenzepine.
TLDR
The ability of pirenzepine to distinguish muscarinic receptor sites in the central nervous system from those of the heart is confirmed, which suggests an important role of cholinergic mechanisms in the regulation of GH secretion. Expand
Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.
TLDR
Alleviation of the dose-limiting peripheral side effects of the anti-Parkinsonian drugs bromocriptine and levodopa, enables a higher optimum dose, with consequent improvement in Parkinsonian symptoms. Expand
Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis
TLDR
Serum prolactin and cytokine, chemokine and growth factor levels in sera from MS patients enrolled in two clinical trials who were treated with domperidone, a generic drug that increases systemic Prolactin levels were analyzed. Expand
Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk.
TLDR
In one-third of mothers, domperidone did not increase milk production, and there was a trend for a dose-response relationship, and infant exposure via breastfeeding was not considered to be significant. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
[Preliminary pharmacokinetics of metoclopramide in humans. Plasma levels following a single oral and intravenous dose (author's transl)].
TLDR
The present data suggest that under the conditions employed in this study metoclopramide is bioavailable by only about 50%; a "first-pass" metabolism is indicated. Expand
Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.
TLDR
It is concluded that domperidone, though a very potent and specific dopamine antagonist, cannot readily cross the blood brain barrier, which thus prevents the occurrence of central effects. Expand
Sustained elevation of serum prolactin by metoclopramide: a clinical model of idiopathic hyperprolactinemia.
TLDR
Elevated serum PRL levels were maintained as long as metoclopramide was continued and returned to the normal range 24 h after cessation of the drug; no change in serum TSH values occurred during repeated metoclobramide ingestion. Expand
Comparison of metoclopramide with other dynamic tests of prolactin secretion.
TLDR
A 10 mg dose produces a larger, more sustained increment in serum PRL than other agents used to evaluate prolactin reserve, and metoclopramide may be useful for dynamic testing of PRL release. Expand
BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASE
TLDR
Peripheral blockade of dopamine receptors is a promising means of limiting the adverse side-effects of the treatment of parkinsonism with central dopaminergic receptor stimulating agents such as bromocriptine. Expand
INFLUENCE OF HYPERPROLACTINAEMIA DUE TO METOCLOPRAMIDE ON GONADAL FUNCTION IN MEN
TLDR
While the metoclopramide‐induced hyperprolactinaemia could be the cause of the observed changes in semen and erectile activity, it is possible that this dopamine receptor blocking drug might directly affect central or peripheral mechanism of erection, the testes or accessory organs. Expand
Differential effects of dopamine antagonists on prolactin secretion from cultured rat pituitary cells.
TLDR
The present findings indicate that prolactin secretion from cultured pituitary cells may provide an in vitro test system suitable to differentiate antagonists of dopamine receptors and possibly to distinguish pure from partial antagonists. Expand
Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.
TLDR
A new potent anti-nauseant, which in contrast to available anti-emetics does not provoke extrapyramidal or adrenolytic adverse effects, also enhances gastric emptying motility and appears to be a safe and effective treatment for patients with dyspepsia or vomiting. Expand
Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.
TLDR
The results strongly suggest that dopamine or/and secretin are involved in the local feedback control of gastric motility; the action of secretin may be direct or indirect by release of dopamine. Expand
Neuropharmacological studies on the neuroleptic potential of domperidone (R33812)
TLDR
The results indicate that the method here proposed to evaluate acute toxicity gives reliable results and allows a considerable reduction of the number of animals killed. Expand
...
1
2
3
...